<DOC>
	<DOCNO>NCT02655965</DOCNO>
	<brief_summary>The aim study compare effectiveness pecs block associate general anesthesia term Piritramide consumption compare general anaesthesia alone chronic pain incidence patient undergo either lumpectomy mastectomy associate axillary dissection This double-blind , placebo control study randomise breast cancer subject 1:1 ratio receive `` pecs block '' Ropivacaine 3.5 mg/ml Clonidine 5 µg/ml ( arm A ) versus placebo ( arm B ) .</brief_summary>
	<brief_title>Double-blind Study Assess effectIveness Pectoral Nerves Block After Breast Surgery Piritramide Consumption</brief_title>
	<detailed_description>This double-blind study randomise breast cancer subject 1:1 ratio receive `` pecs block '' 10 ml Ropivacaine 3.5 mg/ml Clonidine 5 µg/ml inject pectoral muscle 20 ml muscle pectoralis minor serratus anterior ( arm A ) versus 10 ml placebo ( NaCl 0.9 % ) inject pectoral muscle 20 ml muscle pectoralis minor serratus anterior ( arm B ) . The pecs block inject surgery . Subjects receive nausea vomit prophylaxy depend Apfel score After surgery , two intervention group receive wake dose Paracetamol ( 1 g ) Diclofenac ( 75 mg ) , present contraindication dose 0.05 mg/kg Piritramide . In recovery room two group benefit Patient Controlled Intravenous Analgesia ( PCIA ) pump - Piritramide allow control analgesia , stop 24 hour postoperatively .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ropivacaine</mesh_term>
	<mesh_term>Pirinitramide</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>1 . Age ≥18 year old 2 . Female 3 . Subjects undergo either conservative nonconservative breast surgery associate axillary dissection 4 . ASA score ≤ 3 5 . Completion necessary screening procedure within 30 day prior randomisation 6 . Adequate Renal Function include : Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) estimate creatinine clearance ≥ 60 ml/min calculate use method standard institution 7 . Adequate Liver Function , include follow parameter : 1 . Total serum bilirubin ≤ 1.5 x ULN unless patient document Gilbert syndrome 2 . Aspartate Alanine Aminotransferase ( AST ALT ) ≤ 1.5 x ULN 3 . Alkaline phosphatase ≤ 2.5 x ULN 8 . Signed informed consent 9 . Willingness ability comply study schedule visit , treatment plan , laboratory test procedures Exclusion criterion : 1 . Any illness medical condition unstable could jeopardize safety patient compliance study requirement 2 . Allergy local anaesthetic 3 . Known allergy hypersensitivity Paracetamol , Diclofenac , Piritramide excipients 4 . Coagulopathy take oral anticoagulant/ antiaggregant within 7 day prior surgery 5 . BMI &gt; 35 kg / m2 6 . Infection near puncture site 7 . Inability understand pain assessment scale ( VAS McGill questionnaire ) 8 . Severe hepatic impairment : elevated transaminase factor V ≤ 50 % 9 . Severe heart failure : NYHA classification III IV and/or LVEF &lt; 50 % 10 . Pregnant lactate woman 11 . Concurrent treatment daily basis chronic opiate type painkiller end 1 month prior surgery 12 . Scheduled breast reconstruction time surgery 13 . Metastatic subject 14 . Subjects breast implant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>lumpectomy</keyword>
	<keyword>mastectomy</keyword>
	<keyword>PECS bloc</keyword>
</DOC>